Biodefense Global Market Report 2024

The biodefense market size has grown strongly in recent years. It will grow from $17.01 billion in 2023 to $18.55 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The historic period's growth can be attributed to heightened government investment in biodefense programs and initiatives, bolstering regulatory frameworks to expedite biodefense product and technology approvals, improved collaboration among government agencies, private sector entities, and academic institutions, and mounting geopolitical tensions and apprehensions regarding bioterrorism.

The biodefense market size is expected to see strong growth in the next few years. It will grow to $26.38 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The forecasted growth can be attributed to several factors, the ongoing emergence of new infectious diseases, further advancements in biotechnology, strengthened international collaboration and funding mechanisms supporting global biodefense efforts, the enhancement and modernization of biodefense infrastructure, increased public awareness and education on biodefense matters, continual evolution of policies and regulatory frameworks to facilitate innovative biodefense technologies, and growing private sector investment in biodefense research and development. Major trends expected in the forecast period include the utilization of AI and machine learning for predictive modeling, threat detection, and the creation of new biodefense tools, integration of telehealth and remote monitoring technologies for early detection and management of biological threats, a focus on developing next-generation vaccines and therapeutics along with AI-driven drug discovery and development processes, and enhanced genomic surveillance and data analytics capabilities.

The biodefense market is anticipated to experience growth due to the persistent threat of emerging infectious diseases. These diseases, caused by various microorganisms such as bacteria, viruses, parasites, or fungi, highlight the ongoing challenges in pathogen control, rapid response strategies, global coordination, and readiness within the biodefense sector. Biodefense is crucial for managing infectious diseases by improving preparedness, early detection, and swift response to biological threats, thus mitigating their impact on public health. For example, in November 2023, the World Health Organization (WHO) estimated a global tuberculosis (TB) case count of around 10.6 million in 2022, affecting millions of individuals worldwide. This recurring threat underscores the driving force behind the growth of the biodefense market.

Leading companies in the biodefense sector are actively developing innovative solutions, such as nasal COVID-19 vaccines, to bolster global readiness against biological hazards. Nasal vaccines offer advantages such as easier administration, potential for mucosal immunity, reduced reliance on needles, increased accessibility, and potentially enhanced immune responses. For instance, Bharat Biotech International Limited launched the iNCOVACC Nasal COVID-19 vaccine in January 2023. This vaccine, developed using a recombinant replication-deficient adenovirus vector with a pre-fusion stabilized spike protein, underwent successful phase I, II, and III trials. Administered via nasal drops, it involves a 2-dose series given 4 weeks apart, with 4 drops into each nostril.

In September 2022, Emergent BioSolutions Inc. acquired worldwide rights to the TEMBEXA (brincidofovir) smallpox oral antiviral drug from Chimerix for $238 million. This acquisition underscores Emergent BioSolutions' commitment to advancing public health initiatives and addressing global health threats, particularly against smallpox outbreaks. Chimerix Inc., a biotechnology research company, is known for providing biodefense solutions.

Major companies operating in the biodefense market are Pfizer Inc., Johnson & Johnson, Merck & Co., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca Plc, GSK plc, Gilead Sciences Inc, Biogen Inc, Novavax Inc, Ichor Medical Systems, Emergent BioSolutions Inc., Alnylam Pharmaceuticals Inc., Dynavax Technologies, Bavarian Nordic, Siga Technologies Inc., Elusys Therapeutics Inc., Ology Bioservices, Altimmune Inc., Hytest Limited, XOMA Corporation, Cleveland BioLabs Inc., Inovio Pharmaceuticals Inc, Dynport Vaccine Company, ViralClear Pharmaceuticals.

North America was the largest region in the biodefense market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biodefense market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biodefense market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Biodefense encompasses strategies and measures aimed at safeguarding against biological threats, including intentional releases of pathogens or biotoxins. These efforts involve developing detection systems, vaccines, treatments, and emergency response plans to minimize the impact of biological attacks on public health and safety. Additionally, biodefense includes research and policies to prevent the misuse of biological agents.

The primary types of biodefense include anthrax, smallpox, botulism, radiation or nuclear threats, and others. Anthrax is a severe infectious disease caused by Bacillus anthracis, affecting humans and animals. It can be contracted through skin contact, inhalation, or ingestion of spores. Various biothreat detection devices, such as samplers, detectors, identifiers, assays, and more, are utilized in settings such as hospitals, clinics, ambulatory care centers, and beyond.

The biodefense research report is one of a series of new reports that provides biodefense market statistics, including the biodefense industry's global market size, regional shares, competitors with a biodefense market share, detailed biodefense market segments, market trends and opportunities, and any further data you may need to thrive in the biodefense industry. This biodefense market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biodefense market consists of revenues earned by entities by providing services such as threat assessment, surveillance, training, consultation, strategy development, emergency planning, and facility management. The market value includes the value of related goods sold by the service provider or included within the service offering. The biodefense market also includes sales of detection equipment, personal protective gear, vaccines and pharmaceuticals, biological agent identification kits, biocontainment equipment, emergency response kits, biosecurity systems, and communication systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.